Observationa Study is a Prospective and Multi-institutional Observational Study.

Jeil Pharmaceutical

Status: Completed

Conditions: Heartburn; Erosive Reflux Disease; Acid Regurgitation

Study type: Observational

Funder types: Industry

Identifiers

NCT06952855

JL-JAQ-401

Details and patient eligibility

About

This observational study is a prospective, multi-institutional non intervention study to examine the prescription patterns, corresponding treatment effects and safety in routine clinical practice for patients prescribed for the treatment of gastroesophageal reflux disease.

Full description

The present observational study is designed to check effect and safety for patients who have been prescribed JAQBO for the treatment of erosive gastroesophageal reflux disease.

Enrollment: 5,536 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. An adult over 19 years of age
2. A person who voluntarily provides written informed consent

Exclusion criteria

1. A pregnant woman or a nursing woman
2. A person who is deemed unsuitable for the subject of the study

Trial design

5,536 participants in 1 patient group

1 cohort

Description:

No interventions